DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyrighted Material INDEX Note: Page numbers in bold refer to a text discussion of the entry abatacept, 636, 695 release cotransmitters, 497 acquired immuno deficiency syndrome abciximab (ReoPro), 233 synthesis and metabolism, 498–501 (AIDS), 3, 387, 414, 542, ABC transporters, 263 vesicles, 500 590–591, 638, 659, 678–9 polymorphisms, 263 acetylcholine receptors, 501–4 HIV infection, 382, 659 substrates, 263 muscarinic (mAChR), 189, 321, acrylamide derivatives, 335 absorption, 21, 31–44 339, 360, 478, 486, 498, action potential, 468 rate, 39, 74 503, 524, 604 activator protein 1 (AP-1), 630 time constant, 74 muscarinic agonists acyclovir, 15, 655–6 absorption distribution metabolism and (parasympathomimetics), Acyl-CoA-cholesterol-acyltransferase elimination (ADME), 671, 695, 504, 506–7 (ACAT), 448 700–707 muscarinic antagonists inhibitors, 448–9 absorption distribution metabolism (parasympatholytics), 338, 498, adalimumab, 239, 627, 636, 695 excretion and toxicity 504, 506–7 adamantanes, 656–7 (ADMET), 701 muscarinic autoreceptors, 501 adaptation, 42, 118, 121–9, 580, 582, 648 abuse see dependence muscle-type receptor, 503 adaptor protein, 112, 113, 118, 218, 219, acamprosate, 128–9 nicotinic, 112, 126, 140, 179, 180, 182, 231, 434 acarbose, 458, 460 184, 186–7, 504–6 addiction, 7, 122–9, 583, 584 acceptable daily intake (ADI), 669 nicotinic (nAChR), 501–3 adefovir, 659 ACE see angiotensin-converting enzyme nicotinic agonists, 504 adenine nucleotide translocase (ANT), (ACE) nicotinic antagonists, 504 411, 436 acebutol, 325, 492–3 nicotinic autoreceptors, 501 adenosine, 157, 190, 192, 336, 501, aceclidine, 504 COPYRIGHTEDacetylcholinesterase (AChE), 65,MATERIAL 137, 359, 553–64, 656 acetylation, 62, 67, 135 497–8, 507, 692 adenosine deaminase (ADA), 304, 419, 555–6 histone acetyltransferase, 135 inhibitors (AChEIs), 499–500, 505, 526 ADA deficiency syndrome, 563 histone deacetylase, 135 acetylcholine transporters, 360 adenosine diphosphate (ADP), 554–64 acetylcholine (ACh), 190, 194, 496–501, vesicular ACh transporter 1 (VAChT1), adenosine kinase, 556 512, 513, 515 498, 500 adenosine monophosphate (AMP), 555–64 binding protein, 116, 179 acetyl-CoA, 67, 440, 441, 497, 499, 653 adenosine triphosphate (ATP), 190, ganglionic neurotransmission, 479, 503, 506 acetyl-CoA transporter (ACATN), 499 553–64 precursors, 499 acetylprocainamide, 338 adenylate kinase, 555 release, 118, 321, 351, 475, 479, acidification, 56, 161, 169, 355–6, 381, adenylyl cyclase, 195–6 487, 488, 501, 512, 580 475, 684 adesleukin, 638 General and Molecular Pharmacology: Principles of Drug Action, First Edition. Edited by Francesco Clementi and Guido Fumagalli. © 2015 John Wiley & Sons, Inc. Published 2015 by John Wiley & Sons, Inc. 0002534462.indd 714 5/11/2015 2:38:20 PM INDEX 715 adherent junctions see junctions adrenocorticotrope hormone (ACTH), 190, amisulpride, 517–18 adhesion molecules, 219, 220, 222, 227, 221, 481, 489, 494, 523, 567, amitriptyline, 35, 49, 71, 338, 486, 515, 229, 233, 324, 466, 473, 523, 570, 574 517–18, 682 628, 634, 636 adverse reactions, 7, 36, 259, 262, 290, amoxicillin, 34, 642 adhesive receptors, 225–6 291, 682, 698 AMPA receptors see glutamate receptors drug targeting, 233–4 affinity, 95, 96, 99, 101, 103, 104, 107, 108 amphetamines, 124, 126, 361, 366, 485, 515 adipocytes, 282, 393, 458, 460, 563, 586, agomelatine, 517 3,4-methylenedioxy-N- 609, 619 agonist, 102 ethylamphetamine (MDEA), 515 adrenocorticotropic hormone (ACTH), agonists 3,4-methylenedioxy-N- 190, 221, 481, 489, 494, 523, inverse, 107–8 methylamphetamine (MDMA), 567, 570, 574 partial, 104–5 122, 124, 366, 370, 515 administration routes, 31–43 Agouti-related peptide (ARP), 569 amphotericin B, 651–4, 661 dermal route, 37–8 AIDA, 550 ampicillin, 14, 34, 642, 679, 685 drip injection, 35 AIDS see acquired immuno deficiency amprenavir, 387, 393 drug delivery, 42–3 syndrome (AIDS) anacetrapib, 449–50 drug targeting, 43 A-kinase-anchoring protein (AKAP), 196, 198 anakinra, 628, 636, 695 enteral route, 33 Akt, 169, 170, 413 analgesia, 576–9 inhalation route, 36–7 alanine (β-), 365 anandamide (AEA), 112, 585–7, 587, 593–5 intradermal route, 36 Albright’s hereditary osteodystrophy, 194 anaphylaxis, 492, 573, 629 intramuscular route (i.m.), 36 albumin, 21, 50, 55, 59, 243, 290, 421, androgen receptor, 272, 281 intravascular route (i.v.), 35 614, 681 poly-Q tract polymorphism, 281 mucosal routes, 38 alcohol dehydrogenase, 65, 574 androgens, 272, 281, 283, 672 oral route, 33–5 alcoholism, 574 anesthetics, 12, 21, 31, 33, 37, 94, 319, parenteral routes, 35–6 aldehyde dehydrogenase, 514 321, 323–6, 336, 437, 491, 534, rectal route, 35 aldosterone, 167, 273, 280, 479, 493 540, 549, 567 subcutaneous route, 36 alefacept, 628, 636 general, 336, 534, 536–7, 540 sublingual route, 35 aleglitazar, 448 local, 3, 21, 33, 37, 94, 319, 323–6, 329, systemic administration, 31 alemtuzumab, 239, 628, 636, 695 437, 491 topical/regional routes, 31, 37 alfentanil, 573 angina, 492–3, 602 transcutaneous route, 37–8 alfuzosin, 492 angiotensin-converting enzyme (ACE), adrenal cortex, 280, 386 alkalinization of urine, 56, 169, 684 264, 381, 386, 567 adrenaline, 321, 371–2, 452, 478, 484–5, alkylamines, 527, 651 inhibitors, 15, 42, 264, 347, 349, 386, 492, 685 alkylating agents, 417 679–80 adrenal medulla, 168, 373, 478, 479, 496, allopurinol, 629, 683 angiotensin II, 15, 190, 199–200, 381, 386, 574, 620 allosteric modulators, 102, 103 479, 571, 603, 609 adrenergic and noradrenergic systems, agonist, 103 animal models, 15, 46, 163, 254, 275, 290, 480–481 antagonists, 103 298, 326, 328, 413, 442, 443, control of pituitary functions, 481 potentiators, 103 449, 461, 539, 569, 590, 592, depression, wakefulness and feeding almotriptan, 517 619, 637, 702 behavior, 481 alprazolam, 71, 157, 539, 685 animal testing see toxicity distribution, 480 alteplase, 694–5 antagonists, 102 functions, 480 alternative splicing, 115, 167, 203, 237, competitive, 102 adrenergic receptors, 487 286, 351, 456, 499, 566, 619 insurmountable, 102–3 α-adrenergic receptors, 190, 191, 194, 487 alternatives to animal experiments, 672 surmountable, 102 α1 agonists, 490 Alzheimer’s disease, 169, 505 antazoline, 527 α2 agonists, 491 amanita muscaria, 501 anthracenediones, 416, 423 α antagonists, 491 amantadine, 656 anthracyclines, 416, 422–3, 437, 679 β-adrenergic receptors, 190–192, 194, ambenonium, 500, 505 antiarrhythmic drugs, 320, 338 196, 198–200, 488 amidepsine, 440, 446 class II: β-adrenergic antagonists, 15, β1, 264 amikacin, 642, 647 251, 263, 264, 325, 349, 493 β2, 265 amiloride, 49, 320, 354–6, 399, 557, 600 class III: VGKC blockers, 320, 325 β2 agonists, 491 amineptine, 366 class IV antiarrhythmic: VGCC β antagonists, 15, 251, 263, 264, 325, amine transporters, 360 blockers, 320, 325 349, 493 aminoethyl-hydroxyindole, 509 class I: VGSC blockers, 323, 325 β1 polymorphisms, 264 aminoglycosides, 642–3, 647, 679 antibiotics, 4, 13, 14, 26, 36, 37, 49, 56, β2 polymorphisms, 265 aminopyridine, 147, 320, 336, 505 263, 422, 641–60 drugs and therapeutic use, 490–493 aminopyrine, 612 antineoplastic, 422 functions, 489 amiodarone, 49, 71, 320, 325, 338, 354–5, cytoplasmic membrane function localization, 489 681–3 inhibitors, 649–50 0002534462.indd 715 5/11/2015 2:38:20 PM 716 INDEX antibiotics (cont’d ) antiviral drugs, 654–60 association constant, 95 DNA synthesis and replication anti HBV, 659 astemizole, 337–8 inhibitors, 649 anti HCV, 658–9 asthma, 233, 264–5, 280, 290–291, 335, mechanism of action, 642–3 interferons, 659 339–40, 384, 491–3, 506–7, 524, peptidoglycan polymerization NS5B inhibitors, 658 526, 561–4, 570, 573, 600, inhibitors, 645 NS3/4 inhibitors, 658 615–16, 618, 620, 628, 636, 679 peptidoglycan synthesis inhibitors, anti HIV, 659 astrocyte, 362, 369, 466–7, 592, 598, 603 643–5 integrase inhibitors, 660 ataxia telangiectasia, 286 resistance, 650 protease inhibitors, 393 atenolol, 27, 57, 89, 98, 325, 346, 392, ribosomes, 647 reverse transcriptase inhibitors, 659 492, 493 transcription inhibitors, 646 virus entry inhibitors, 660 atorvastatin, 71, 440–441, 450, 685 translation inhibitors, 646–9 anti influenza virus, 656–7 ATP binding cassette, 263, 345, 493 antibodies, 636 mechanism of action, 654–5 atracurium, 504, 506 monoclonal (mAbs), 17, 113, 115, resistance, 656–60 atrial natriuretic peptide, 114 213–15, 233, 239, 417, 427–8, anxiety, 14, 363, 481, 493–4, 511, 517, atropine, 57, 491, 498, 504–8, 680 635, 639, 695 529, 532–4 methylnitrate, 506, 507 monoclonal humanized, 239 Apaf-1, 408, 411 autacoids see specific agents monoclonal therapeutic, 239 apamin, 339 autoimmunity, 626 polyclonal, 635 apolipoproteins, 443, 448, 540 autonomic nervous system, 343, 477–95, anticholinergic agents, 7, 34, 486, 498, apomorphine, 489, 494, 540 553, 609, 619 504, 507, 527, 680 apoptosis, 389, 558, 562–3 avasimibe, 449 antidepressants, 14, 15, 34, 35, 61, 259, regulators, 409 avidity, 48, 52, 81 263, 338, 364, 366, 370–372, apoptosis-inducing factor (AIF), 411 azacytidine (Vidaza), 426 481, 486, 511–12, 515, 515–19 apoptotic bodies, 407 azathioprine, 62, 262, 626–31, 635–6, 679 antidotes, 684 eat me signals, 408 azimilide, 325, 337–8 antiemetics, 65, 263, 338, 517 picnosis, 408 azithromycin, 634, 642, 683–4 antiepileptic drugs, 51, 320, 322–3, 325, apoptotic pathway, 408–11 azoles, 651–4 327, 369, 472, 530, 539 extrinsic pathway, 408, 409 aztreonam, 642 antifungal drugs, 338, 651–4 intrinsic mitochondrial pathway, acting on cytoplasmic membrane, 652–3 408, 411 bacitracin, 642 DNA and protein synthesis apraclonidine, 492 baclofen, 531, 533, 537–40
Load more

Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • DE H 2281 001 PAR.Pdf
    Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure RMS Public Assessment Report Latanoprost Malcosa 0,005% Xalaprost 0,005% Laxatan 0,005% Pharmecol 0.005% DE/H/1999/001/DC DE/H/2281/001/DC DE/H/2282/001/DC DE/H/2382/001/DC Applicant: Malcosa Ltd. Reference Member State DE Date of this report: 06.12.2010 The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health. 1/30 CONTENTS ADMINISTRATIVE INFORMATION .............................................................................................. 3 I. RECOMMENDATION ................................................................................................................ 4 II. EXECUTIVE SUMMARY....................................................................................................... 4 II.1 Problem statement..................................................................................................................... 4 II.2 About the product ..................................................................................................................... 4 II.3 General comments on the submitted dossier .......................................................................... 5 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles..6 III. SCIENTIFIC OVERVIEW AND DISCUSSION ................................................................... 6 III.1 Quality aspects......................................................................................................................
    [Show full text]
  • A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies
    Neuropsychopharmacology (2016) 41, 1803–1812 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies ,1 1 2 3 4 Anke Post* , Trevor S Smart , Judith Krikke-Workel , Gerard R Dawson , Catherine J Harmer , 3,4 1 5 6 6 1 Michael Browning , Kimberley Jackson , Rishi Kakar , Richard Mohs , Michael Statnick , Keith Wafford , 1 6 6 Andrew McCarthy , Vanessa Barth and Jeffrey M Witkin 1 2 3 4 5 Lilly UK, Windlesham, Surrey, UK; Eli Lilly, Netherlands; P1vital Limited, Oxfordshire, UK; University of Oxford, Oxford, UK; Innovative Clinical 6 Research-SICR, Ft. Lauderdale, FL, USA; Neuroscience Research, Eli Lilly and Company, Indianapolis, IN, USA Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand of the N/OFQ peptide (NOP) receptor, which is a G protein-coupled receptor in brain regions associated with mood disorders. We used a novel, potent, and selective orally bioavailable antagonist, LY2940094, to test the hypothesis that blockade of NOP receptors would induce antidepressant effects. In this study we demonstrate that targeting NOP receptors with LY2940094 translates to antidepressant-like effects in rodent models and, importantly, to antidepressant efficacy in patients with major depressive disorder (MDD). The proof-of-concept study (POC) was an 8-week, double-blind, placebo- controlled trial that evaluated LY2940094 as a novel oral medication for the treatment of patients with MDD. Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo provided some evidence for an antidepressant effect based on the change from baseline to week 8 in the GRID-Hamilton Depression Rating Scale-17 item total score, although the predefined POC efficacy criterion (probability of ⩾ LY2940094 being better than placebo 88%) was not met (82.9%).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • Drugs for Glaucoma
    Australian Prescriber Vol. 25 No. 6 2002 Drugs for glaucoma Ivan Goldberg, Eye Associates and Glaucoma Service, Sydney Eye Hospital and the Save Sight Institute, University of Sydney, Sydney SYNOPSIS is not uncommon and the pressure slowly rises. Withdrawing Older drugs for glaucoma reduce intra-ocular pressure, the drug for a few months often re-establishes its efficacy. but often have unpleasant adverse effects. They still The main problem with timolol or levobunolol is their potential have a role in therapy, but there are now newer for systemic adverse effects. These are the same as the adverse drugs which overcome some of the problems. The topical effects of oral beta blockers, the most important of which are carbonic anhydrase inhibitors decrease the secretion of bronchoconstriction, bradyarrhythmias, and an increase in aqueous humour, while lipid-receptor agonists increase falls in the elderly. uveoscleral outflow. Alpha agonists use both mechanisms 2 As betaxolol is relatively selective for beta1 receptors it should to reduce intra-ocular pressure. If a patient needs more pose less respiratory risk. Its pharmacokinetic properties than one drug to control their glaucoma, the new drugs (higher plasma binding and larger volume of distribution) also generally have an additive effect when used in combination make it less likely to provoke other systemic effects. regimens. Miotics Index words: beta blockers, carbonic anhydrase inhibitors, Miotics (pilocarpine and carbachol) are rapidly falling out of lipid-receptor agonists. favour. While their ocular hypotensive efficacy is undisputed, (Aust Prescr 2002;25:142–6) and their systemic safety margin wide (abdominal cramping or diarrhoea are rarely reported), their use is declining because Introduction of their local effects and the need to instill them up to four Glaucoma is the second commonest cause of visual disability times daily.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Intravta Deltorphin, but Not DPDPE, Induces Place Preference in Ethanoldrinking Rats
    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 38, No. 1 January 2014 Intra-VTA Deltorphin, But Not DPDPE, Induces Place Preference in Ethanol-Drinking Rats: Distinct DOR-1 and DOR-2 Mechanisms Control Ethanol Consumption and Reward Jennifer M. Mitchell, Elyssa B. Margolis, Allison R. Coker, Daicia C. Allen, and Howard L. Fields Background: While there is a growing body of evidence that the delta opioid receptor (DOR) modu- lates ethanol (EtOH) consumption, development of DOR-based medications is limited in part because there are 2 pharmacologically distinct DOR subtypes (DOR-1 and DOR-2) that can have opposing actions on behavior. Methods: We studied the behavioral influence of the DOR-1-selective agonist [D-Pen2,D-Pen5]- Enkephalin (DPDPE) and the DOR-2-selective agonist deltorphin microinjected into the ventral tegmental area (VTA) on EtOH consumption and conditioned place preference (CPP) and the physio- logical effects of these 2 DOR agonists on GABAergic synaptic transmission in VTA-containing brain slices from Lewis rats. Results: Neither deltorphin nor DPDPE induced a significant place preference in EtOH-na€ıve Lewis rats. However, deltorphin (but not DPDPE) induced a significant CPP in EtOH-drinking rats. In con- trast to the previous finding that intra-VTA DOR-1 activity inhibits EtOH consumption and that this inhibition correlates with a DPDPE-induced inhibition of GABA release, here we found no effect of DOR-2 activity on EtOH consumption nor was there a correlation between level of drinking and deltorphin-induced change in GABAergic synaptic transmission. Conclusions: These data indicate that the therapeutic potential of DOR agonists for alcohol abuse is through a selective action at the DOR-1 form of the receptor.
    [Show full text]
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]